Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy
- PMID: 30581985
- PMCID: PMC6292824
- DOI: 10.1016/j.omto.2018.11.002
Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy
Figures
References
-
- Piette J., Neel H., Maréchal V. Mdm2: keeping p53 under control. Oncogene. 1997;15:1001–1010. - PubMed
-
- Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237–1245. - PubMed
-
- Gramantieri L., Ferracin M., Fornari F., Veronese A., Sabbioni S., Liu C.G., Calin G.A., Giovannini C., Ferrazzi E., Grazi L.G. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007;67:6092–6099. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
